September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Paolo Tarantino: More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i
Nov 19, 2023, 17:20

Paolo Tarantino: More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i

Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X/Twitter:

Capivasertib is now approved in combo with fulvestrant for pts with pretreated ER+/HER2- MBC whose tumor has an alteration in PIK3CA, AKT1 or PTEN (approx 40%).

More important than ever to perform NGS/ctDNA to select the best 2L treatment after CDK4/6i.”

For more information click here.
Source: Paolo Tarantino/Twitter